Swiss pharmaceutical major Roche has secured a landmark US regulatory approval for its drug Gazyva/Gazyvaro (obinutuzumab), making it the first and only treatment for primary membranous nephropathy (pMN), a rare autoimmune kidney disease.
The FDA approval is for adults with pMN who are at risk of disease progression, with the treatment aimed at inducing remission of proteinuria, a key indicator of kidney damage.
The approval marks a significant breakthrough for patients with the chronic condition, which, if left untreated, can result in kidney failure in up to 30% of cases within 10 years.
The regulatory clearance is backed by results from Roche’s Phase III MAJESTY trial, which demonstrated that Gazyva/Gazyvaro was significantly more effective than tacrolimus in achieving complete remission of proteinuria after two years.
The study found that 36.1% of patients receiving Gazyva/Gazyvaro achieved complete remission at 104 weeks, compared with just 5.7% among those treated with tacrolimus. The difference was statistically significant.
The drug also demonstrated superiority in overall remission rates, with 50% of patients achieving complete or partial remission at two years, compared with 12.9% in the tacrolimus group.
“The FDA approval of Gazyva/Gazyvaro represents an important step forward for people living with primary membranous nephropathy, where targeting B cells addresses a critical underlying driver of disease,” said Levi Garraway, Roche’s Chief Medical Officer and Head of Global Product Development.
“With Gazyva/Gazyvaro, we are turning decades of specialised antibody engineering into tangible outcomes for patients with immune-mediated kidney diseases. By achieving significantly higher complete remission rates compared to tacrolimus, Gazyva/Gazyvaro offers a more effective approach to help achieve durable disease control.”
The MAJESTY trial enrolled 142 adults, randomly assigning them to receive either Gazyva/Gazyvaro or tacrolimus. Its findings were presented at the 63rd European Renal Association Congress in June 2026 and published in the New England Journal of Medicine.
The safety profile of Gazyva/Gazyvaro was consistent with previous findings, with no new safety signals identified.
The approval is being hailed as a major milestone for patients who have historically had limited treatment options specifically approved for pMN.
“People living with primary membranous nephropathy face the risk of progressive kidney damage and significant uncertainty about their health,” said Marc Hurlbert, Chief Executive Officer of the National Kidney Foundation.
“The first FDA approval of a treatment specifically for this condition is a milestone, finally giving patients and clinicians more treatment options. Our hope is that the approval of Gazyva/Gazyvaro provides a turning point for people navigating pMN.”
Primary membranous nephropathy is an autoimmune disorder in which the body's immune system attacks the kidney's filtering units, known as glomeruli. This causes protein to leak into the urine and can progressively impair kidney function.
Patients commonly experience fatigue, swelling and significant physical, emotional and social challenges. The disease can also trigger serious complications, including blood clots, cardiovascular disease and kidney failure.
Roche said achieving complete remission is critical to preserving kidney function and delaying or preventing potentially life-threatening complications.
“pMN can lead to debilitating physical and psychological symptoms that place a heavy burden on patients, families and healthcare systems alike,” said Teresa Graham, Chief Executive Officer, Roche Pharmaceuticals.
“This first-ever FDA approval delivers an important targeted treatment option for the pMN community and expands how many people may benefit from Gazyva/Gazyvaro across multiple severe immune-mediated kidney diseases.”
The latest approval further expands Roche's presence in immune-mediated kidney diseases. It is the third FDA approval for Gazyva/Gazyvaro in this therapeutic area, following approvals for idiopathic nephrotic syndrome and lupus nephritis.
Roche said data from the MAJESTY study are also being submitted to other global regulatory authorities, including the European Medicines Agency.
The company is positioning the latest approval as further validation of its strategy to develop targeted therapies against B cells, which play a central role in several autoimmune diseases.